Modern Value Investing with Sven Carlin

Zoetis decline tests the case for long-term value

Zoetis ZTS - 15% Yearly Returns For The Next 15 Years

The episode examines whether Zoetis’s durable veterinary demand and shareholder returns can outweigh pharmaceutical, regulatory, and valuation risks over 15 years.

3 key takeaways
  1. 1Zoetis combines strong returns on invested capital with steady earnings, durable veterinary demand, and a developing product pipeline.
  2. 2Sven Carlin argues that dividends, buybacks, and business growth could support roughly 15% annual returns over the next 15 years.
  3. 3Patent expirations, regulation, competition, and pharmaceutical volatility remain central risks despite Zoetis’s attractive valuation and market position.

Don't miss

Sven Carlin argues that Zoetis’s growth, dividends, and buybacks could support roughly 15% annual returns for the next 15 years.

The brief

Zoetis’s sharp decline has brought the animal-health company into focus as a potential long-term value investment, with Michael Burry’s interest adding to the debate.

Sven Carlin reviews Zoetis’s earnings, margins, returns, guidance, capital spending, pipeline, patent expirations, and convertible debt used to fund repurchases.

The core argument rests on a combination of veterinary-medicine growth, dividends, buybacks, and a lower valuation that could produce roughly 15% annual returns.

The case is not risk-free: pharmaceutical volatility, regulatory changes, competition, and patent expirations could challenge the company’s growth and market position.

Carlin places Zoetis in his value-investing framework and concludes that its profitability, high returns on invested capital, and valuation make it attractive to long-term investors.

What was said on this episode

7 statements · 6 positive · 1 negative

  1. Sven Carlinon ZoetisNegative1:58

    Zoetis has slightly reduced its guidance.

    “guidance has been revised a little bit just slightly down”

    Listen at 1:58

  2. Sven Carlinon ZoetisPositive3:09

    Zoetis appears cheap at a price-to-earnings ratio of 12.

    “all of that with a P ratio of 12 looks cheap.”

    Listen at 3:09

  3. Sven Carlinon veterinary medicine marketPositive3:17

    The veterinary medicine market is projected to grow 10.73%.

    “the growth of just the market for veterinary medicine is projected at 10.73%.”

    Listen at 3:17

  4. Sven Carlinon ZoetisPositive3:30

    Seven-percent growth plus buybacks and dividends could produce 12% returns.

    “if we look at not 10% growth, but 7% growth, plus buybacks, plus the dividend, that's already 12%.”

    Listen at 3:30

  5. Sven Carlinon ZoetisPositive3:59

    Zoetis may offer approximately 10% returns with market-like risk.

    “to be more conservative 10 market like risk”

    Listen at 3:59

  6. Sven Carlinon ZoetisPositive4:34

    Zoetis is profitable, growing, well-positioned, and has high returns on invested capital.

    “If you want a good business, high return on invested capital, good position, profitable, growing, good market, everything good”

    Listen at 4:34

  7. Sven Carlinon ZoetisPositive4:54

    Zoetis appears to be a buy.

    “looks like a buy.”

    Listen at 4:54

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.